<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797771</url>
  </required_header>
  <id_info>
    <org_study_id>NM-HU-01</org_study_id>
    <nct_id>NCT00797771</nct_id>
  </id_info>
  <brief_title>User Satisfaction Using the ADI Insulin Pump</brief_title>
  <official_title>Evaluation of User Satisfaction Using the ADI Insulin Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NiliMedix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NiliMedix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 250,000 people worldwide are currently being treated with an insulin pump. This&#xD;
      number is growing dramatically as these devices become smaller and more user-friendly.&#xD;
      Insulin pumps allow for tight metabolic control and lifestyle flexibility while minimizing&#xD;
      the number of hypoglycemic events.&#xD;
&#xD;
      The NiliMedix ADI Insulin Pump is an ambulatory, battery operated, rate programmable micro-&#xD;
      infusion pump, designed for continuous delivery of insulin. A custom reservoir is driven by&#xD;
      the pressure of insulin within it to deliver preset basal profiles and patient programmed&#xD;
      bolus of insulin through custom infusion sets, into subcutaneous tissue.&#xD;
&#xD;
      This type of device requires extensive user interaction and education in order to ensure its&#xD;
      safety. This study was designed to test the independent home-use of the NiliMedix ADI Insulin&#xD;
      Pump, and to evaluate user's satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>User satisfaction regarding the &quot;Adi&quot; pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemic events</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Adi&quot; insulin pump users</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;Adi&quot; Insulin pump</intervention_name>
    <description>insulin delivery will be defined by the physician</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female age 18 years and up.&#xD;
&#xD;
          -  Subject is diagnosed as Type 1 Diabetes.&#xD;
&#xD;
          -  Pump Users for at least 6 months&#xD;
&#xD;
          -  HbA1c: less than 8.5%&#xD;
&#xD;
          -  Capable of reading pump screens in English.&#xD;
&#xD;
          -  Subject understands the study procedure.&#xD;
&#xD;
          -  Subject is willing to sign the informed consent form and comply with the study&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major physical, motor, mental, behavioral, or psychiatric limitations.&#xD;
&#xD;
          -  Subject experienced a severe hypoglycemic episode that led to hospitalization during&#xD;
             the last 6 months.&#xD;
&#xD;
          -  Subject experienced an episode of Ketoacidosis during the last 6 months, while using&#xD;
             an insulin pump.&#xD;
&#xD;
          -  Concurrent additional major illness.&#xD;
&#xD;
          -  Subject objects to the study protocol.&#xD;
&#xD;
          -  Physician objection&#xD;
&#xD;
          -  Concurrent participation in other study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomit Shalitin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schnieder Children's Medical Center Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schnieder Children's Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 23, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hanna Levy</name_title>
    <organization>NiliMedix</organization>
  </responsible_party>
  <keyword>Insulin delivery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

